Table 3 Overview of the medication applied in the TAK cohort
Treatment | At diagnosis | Accumulated | At last visit | |||
|---|---|---|---|---|---|---|
cohort | Early | Late | Early | Late | Early | Late |
Prednisolone p.o, n (%) | 14 (70) | 59 (86) | 24 (100) | 63 (91) | 16 (67) | 53 (77) |
Metylprednisone i.v. n (%)a | 0 | 17 (25)** | 2 (8) | 22 (32)** | 0 | 1 (1.4) |
Any DMARDs, n (%) | 1 (4) | 35 (51)*** | 13 (54) | 61 (88)*** | 7 (29) | 51 (74)*** |
Methotrexate | 1 (4) | 28 (41)*** | 11 (46) | 55 (80)*** | 5 (21) | 42 (61)*** |
Azathioprine | 0 | 7 (10) | 7 (29) | 18 (26) | 2 (8) | 8 (12) |
Mycophenelate mofetil | 0 | 1 (4) | 3 (4) | 0 | 1 (1.4) | |
Cyclophosphamideb | 2 (8) | 6 (9) | 4 (17) | 7 (15) | 0 | 0 |
Any biologic, n (%) | 0 | 0 | 3 (13) | 30 (44)* | 3 (13) | 23 (33)* |
Infliximab | 0 | 0 | 2 (8) | 29 (42)** | 1 (4) | 16 (23)* |
Etanercept | 0 | 0 | 2 (8) | 3 (4) | 1 (4) | 1 (1.4) |
Adalimumab | 0 | 0 | 1 (4) | 3 (4) | 1 (4) | 3 (4) |
Tocilizumab | 0 | 0 | 1 (4) | 5 (7) | 0 | 3 (4) |
Other medication, n (%) | ||||||
Acetylsalicylic acid | 2 (8) | 32 (46)** | 16 (67) | 47 (68) | 13 (57) | 41 (59) |
Statin | 1 (4) | 16 (23) | 16 (67) | 34 (49) | 13 (57) | 32 (46) |